What is Phathom Pharmaceuticals, Inc.'s G&A?

Phathom Pharmaceuticals, Inc. (PHAT) reported G&A of $23.4M in Q3 2023.

How has Phathom Pharmaceuticals, Inc.'s G&A changed year-over-year?

Phathom Pharmaceuticals, Inc.'s G&A decreased by 0.5% year-over-year, from $23.51M to $23.4M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Phathom Pharmaceuticals, Inc. PHAT G&A

Discontinued — last reported Q3 '23

G&A at other companies

AMP

Amphastar PharmaceuticalsAMPH

$18.03M+12.7%

Ligand PharmaceuticalsLGND

$20.84M+10.8%

PVL

Palvella TherapeuticsPVLA

$5.52M+45.4%

Segments

By segment

See full

Reportable Segment Aggregation Before Other Operating$7.03M-20.1%

Other financials

Income statement

See full

Revenue$58.3M+104%

Gross profit$46.3M+86.8%

Operating income-$15.5M+80.4%

Net income-$30.4M+67.8%

EPS (diluted)-$0.37+71.8%

Balance sheet

See full

Cash & equivalents$180.9M-14.8%

Total debt$166.3M-18.3%

Total equity-$337.0M+0.4%

Total assets$305.1M+3.7%

Cash flow

See full

Operating cash flow-$15.6M+81.6%

CapEx$61.0K+239%

Free cash flow-$15.7M+81.5%

Valuation

See full

Market cap$824.68M+13.4%

Enterprise value$810.08M+12.7%

P/S4×-4.9×

Profitability

See full

Gross margin84.9%-1.3pp

Operating margin-47.1%-21.9pp

Net margin-76.8%-34.5pp

FCF margin-47.7%-22.1pp

Returns & leverage

See full

Return on equity-147.9%—

Debt / equity5.6×—

Current ratio2.2×-1.4×

Where this comes from

Reported directly by Phathom Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed November 9, 2023, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s G&A?: Phathom Pharmaceuticals, Inc. (PHAT) reported G&A of $23.4M in Q3 2023.
How has Phathom Pharmaceuticals, Inc.'s G&A changed year-over-year?: Phathom Pharmaceuticals, Inc.'s G&A decreased by 0.5% year-over-year, from $23.51M to $23.4M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.